C0103403||Annexin A1
C1518440||nuclear translocation
C0035316||retinal ganglion cell
C0162638||apoptosis
C0349419||ischemia-reperfusion injury
C0011164||degeneration
C0035316||retinal ganglion cells
C0035316||retinal ganglion cells
C0017601||glaucoma
C0103403||annexin A1
C0103403||annexin A1
C1660771||neuronal cell apoptosis
C0035316||retinal ganglion cells
C0162638||apoptosis
C0349419||ischemia-reperfusion
C0021753||IL-1β
C1171362||expression
C1518440||nuclear translocation
C0103403||annexin A1
C0041904||upregulated
C0349419||ischemia-reperfusion
C0035316||retinal ganglion cells
C1515655||in vivo
C0103403||annexin A1
C1171362||expression
C0021753||IL-1β
C1449562||primary cultured
C0035316||retinal ganglion cells
C2930586||ANXA1 shRNA
C0969281||p65 inhibitor BAY 11-7082
C0103403||annexin A1
C0599933||p65
C0007610||nucleus
C0020980||Chromatin immunoprecipitation assay
C0103403||annexin A1
C1334112||IL-1β gene
C0033413||promoter
C1518440||p65 nuclear translocation
C0103403||ANXA1 peptide
C0026882||Ser5Ala mutation
C1171362||expression
C0021753||IL-1β
C0349419||ischemia-reperfusion
C0035316||retinal ganglion cells
C0162638||apoptosis
C1515655||in vivo
C0035316||retinal ganglion cells
C0103403||annexin A1
C0021753||IL-1β
C1171362||expression
C0599933||p65
C0007610||nucleus
C0162638||cell apoptosis
C0040808||treatment strategy
C0035316||retinal ganglion cells
C0162638||apoptosis
C0349419||ischemia-reperfusion injury